USPTO serial 79296355
CARTANA
Reviewed by CopyMark Law Group
Status 402
- Filing date
- Status date
- Registration date
- —
- Examiner
- CIANCI, RYAN MICHAEL
- Law office
- TMO LAW OFFICE 116 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CARTANA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in scientific analysis, research, diagnostics and industrial use; chemicals for in situ RNA sequencing, RNA transcription profiling, detection of RNA in tissue samples, microRNA expression profiling, detection of polymorphisms, analysis of functional pathway gene sets, diagnostics, companion diagnostics; chemicals kits including oligonucleotides, reagent buffers, enzymes, detection solutions, fluorophores for research and diagnostics use and drug development purpose; reagents for microfluidic instruments for non-medical use | SECTION 70 - CANCELLED | — |
| 005 | Diagnostic reagents for medical use in the field of cancer; diagnostic reagents for clinical or medical laboratory use, namely, for in situ RNA sequencing, RNA transcription profiling, detection of RNA in tissue samples, microRNA expression profiling, detection of polymorphisms, analysis of functional pathway gene sets, diagnostics, companion diagnostics; diagnostic reagents for detection of gene mutation for clinical, oncology, and hematology diagnostics; diagnostic reagent kits comprising primarily of diagnostic reagents for medical use in the field of cancer; chemical reagents for medical use; diagnostic test kits for medical use comprising primarily of reagents, slides, solid matrix materials, microfluidic devices sold as a unit; medical diagnostic test kits for detecting pathogens, comprising primarily reagents, slides, solid matrix materials, microfluidic devices sold as a unit; medical diagnostic reagents for in situ RNA sequencing, RNA transcription profiling, detection of RNA in tissue samples, microRNA expression profiling, detection of polymorphisms, analysis of functional pathway gene sets, diagnostics, companion diagnostics; reagents for microfluidic instruments for medical use; kits for research use, diagnostics use and drug development, namely, oligonucleotides, reagent buffers, enzymes, detection solutions and fluorophores; kits for research use, diagnostics use and drug development, namely, oligonucleotides, reagent buffers, enzymes, detection solutions and fluorophores | SECTION 70 - CANCELLED | — |
| 009 | Apparatus and instruments for scientific and diagnostic use; apparatus and instruments used for in situ RNA sequencing, RNA transcription profiling, detection of RNA in tissue samples, microRNA expression profiling, detection of single nucleotide polymorphisms, analysis of functional pathways gene sets, diagnostics, companion diagnostics; appartus and instruments for detection of gene mutation for clinical, oncology, and hematology diagnostics; apparatus, instruments and software used in scientific analysis, RNA expression profiling, detection of RNA, image analysis and cell segmentation for research and diagnostic use; microfluidic instruments for non-medical use; apparatus, instruments and software used in scientific analysis, RNA expression profiling and detection of RNA for research and diagnostic use | SECTION 70 - CANCELLED | — |
| 010 | Apparatus and instruments used for in situ RNA sequencing, RNA transcription profiling, detection of RNA in tissue samples, microRNA expression profiling, detection of single nucleotide polymorphisms, analysis of functional pathways gene sets, diagnostics, companion diagnostics for medical use; microfluidic instruments for medical use | SECTION 70 - CANCELLED | — |
| 042 | Research, development and diagnostics services for others regarding in situ RNA sequencing, RNA transcription profiling, detection of RNA in tissue samples, microRNA expression profiling, detection of single nucleotide polymorphisms, analysis of functional pathways gene sets; drug development; diagnostic and companion diagnostic development; data science (biostatistics) services; laboratory biomarker analysis services and related data analysis; image analysis and cell segmentation services; medical and scientific research | SECTION 70 - CANCELLED | — |
| 044 | Medical services; medical diagnostic services; veterinary services; veterinary diagnostic services | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CartaNA AB
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CARTANA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 14, 2021 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Mar 28, 2021 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Mar 27, 2021 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Mar 20, 2021 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jan 30, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 8, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 8, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 23, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 22, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 16, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 30, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 26, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 22, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |